Endo Reports Third Quarter Financial Results And Updates 2012 Financial Guidance

05 Nov, 2012, 07:00 ET from Endo Health Solutions

CHADDS FORD, Pa., Nov. 5, 2012 /PRNewswire/ -- 

  • Total quarterly revenues of $750 million, decreased 1 percent versus prior year
  • Qualitest quarterly net sales increase by 12 percent versus prior year
  • Reformulated Version of OPANA® ER with INTAC® Technology Designed to be Crush-Resistant Accounts for more than 90 Percent of OPANA ER Total Prescription Volume
  • Company now expects adjusted diluted EPS in the range of $5.00 to $5.10; Now expects reported diluted (GAAP) EPS in the range of $0.87 to $0.97
  • Company now expects revenues of approximately $3.05 billion in 2012

Endo Health Solutions (Nasdaq: ENDP) today reported a 1 percent decrease in total revenues during the third quarter of 2012 to $750 million, compared with $759 million in the same quarter of 2011.  Net income for the three months ended September 30, 2012 was $54 million, compared with net income of $41 million reported in the comparable 2011 period. 

Reported net income includes a benefit of $46 million to reduce a previous non-cash charge associated with the company's LIDODERM® license and settlement agreement with Watson Laboratories, Inc. in accordance with the terms of that agreement.  Reported net income also includes the effect of charges in the amount of $83 million for the period reflecting the settlement of certain legal matters relating to price reporting that were disclosed previously as well as an estimated minimum amount to resolve the ongoing investigation by the government focused primarily on the sale, marketing and promotion of LIDODERM®, which has been disclosed previously.

As detailed in the supplemental financial information below, adjusted net income for the three months ended September 30, 2012 was $153 million, compared with $151 million in the same period in 2011.  Reported diluted earnings per share for the quarter ended September 30, 2012 were $0.45, compared with $0.34 in the third quarter of 2011.  Adjusted diluted earnings per share for the same period were $1.28 compared with $1.25 reported in 2011.

"Endo had a solid third quarter," said Dave Holveck, president and CEO of Endo. "As the team and I outlined at our Investor Day on October 4th, we believe the assets that Endo has assembled to offset the potential loss of exclusivity for LIDODERM provide us with multiple opportunities for growth, the potential for long-term expansion and produce a durable set of cash flows."

 

FINANCIAL PERFORMANCE AT A GLANCE

($ in thousands, except per

share amounts)

3rd Quarter

Nine Months Ended September 30,

2012

2011

Change

2012

2011

Change

Total Revenues

$

750,482

$

759,078

(1)

%

$

2,226,303

$

1,926,715

16

%

Reported Net Income

$

53,809

$

40,649

32

%

$

(24,071)

$

151,019

NM

Reported Diluted EPS

$

0.45

$

0.34

32

%

$

(0.21)

$

1.24

NM

Adjusted Net Income

$

153,093

$

151,089

1

%

$

413,546

$

399,967

3

%

Adjusted Diluted EPS

$

1.28

$

1.25

2

%

$

3.42

$

3.29

4

%

 

ENDO PHARMACEUTICALS

Branded pharmaceutical sales of $417 million for the third quarter represented a decrease of 2 percent versus the prior year.   Net sales of Opana ER decreased 36 percent for the third quarter on 33 percent lower prescriptions.  The decrease in Opana ER net sales is primarily a result of the first quarter supply disruption due to the Novartis plant closure in Lincoln, Neb., and a slower return to growth for Opana ER.

Net sales of LIDODERM increased 15 percent for the third quarter on 5 percent prescription growth.  The increase in LIDODERM net sales is primarily a result of changes with respect to royalty obligations among Endo Pharmaceuticals, Hind Healthcare Inc., and Teikoku Seiyaku Co. Ltd.; changes that began in November 2011 and have been previously described in our filings with the U.S. Securities and Exchange Commission.

During third quarter 2012, Watson announced it had received approval of its ANDA for its lidocaine 5% patch.  Endo anticipates Watson will launch its lidocaine 5% patch in September 2013 pursuant to the terms of the settlement and license agreement resolving all ongoing patent litigation among the parties related to Watson's generic version of LIDODERM. The agreement resolved the inherent uncertainties of this litigation and reflects the uncertainty created by the regulatory challenges facing generic manufacturers seeking to market a generic version of LIDODERM. 

During the third quarter of 2012, Endo announced that according to IMS data estimates, the reformulated OPANA ER (oxymorphone HCI) designed to be crush-resistant incorporating Grunenthal's INTAC Technology accounts for more than 90 percent of the OPANA ER total prescription volume. 

Additionally, Endo Pharmaceuticals has submitted two Citizen Petitions encouraging the FDA to partner with the company in an effort to employ standards that will better manage patient access to vital pain management medications like OPANA ER while also helping drive appropriate use of the products.

In August 2012, BioDelivery Sciences International, Inc. and Endo announced the initiation of the Phase 3 clinical program for BEMA® Buprenorphine for the treatment of moderate to severe chronic pain. This Phase 3 program will consist of two efficacy studies, one in opioid naive and one in opioid experienced subjects. Both studies are anticipated to be completed by late 2013 or early 2014.

As a result of recent discussions with the FDA regarding the current Urocidin phase III clinical trial Endo has decided to end the study before its scheduled completion. Endo, and its partner Bioniche Life Sciences Inc., are considering potential next steps for the program.

QUALITEST

Generic product net sales of $166 million for the third quarter 2012 represented an increase of 12 percent over the same period last year.  The increase was driven by strong demand for our subsidiary Qualitest's diversified product portfolio and favorable pricing, resulting in gross profit of approximately 40 percent.  Strong net sales growth is expected for Qualitest for the remainder of 2012.  Net sales growth is expected to be driven by strong demand for Qualitest's commercial products and a stable pricing environment.  Qualitest remains focused on process improvements and increased efficiencies in order to enhance manufacturing capacity.

In August 2012, Qualitest announced its launch of a generic version of Singulair® (montelukast sodium) Tablets and Chewable Tablets.  Total combined branded and generic sales for Montelukast Sodium Tablets and Chewables in the U.S. for the 12 months ended June 30, 2012 were approximately $4.9 billion, according to IMS Health.

In October 2012, Qualitest received through its partner, Alembic Pharmaceuticals Limited, FDA approval of three products, Irbesartan Tablets, Irbesartan/HCTZ Tablets and Modafinil Tablets. Total combined branded and generic sales for Irbesartan Tablets, Irbesartan/HCTZ Tablets and Modafinil Tablets in the U.S. for the 12 months ended June 30, 2012 were approximately $1.7 billion, according to IMS Health. For Qualitest, new product approvals supplement growth and the continued optimization of Qualitest's commercial portfolio.   

AMS

Devices sales, driven by our June 2011 acquisition of AMS, were $113 million for the third quarter 2012.  Men's Health, led by sales of the AMS 800® Artificial Urinary Sphincter, decreased 12 percent in the third quarter of 2012, compared with same period last year. This declining sales rate for the period reflects the temporary withdrawal of the AMS 800 Artificial Urinary Sphincter from the market during second quarter 2011 and subsequent rebound in third quarter 2011. On a year-to-date pro forma basis, net sales for Men's Health products increased 6 percent, which is more indicative and in-line with the company's expectations for mid-to-high single digit growth.  AMS's benign prostatic hyperplasia (BPH) business, led by the decreasing share of procedural volumes for the GreenLight XPS console and the accompanying MoXy® fiber, decreased 4 percent in the third quarter of 2012.  Women's Health sales decreased 23 percent in the third quarter of 2012, compared with same period last year.  Net sales declines in Women's Health were driven by year-over-year declines in procedural volumes reflecting recent industry shifts following the FDA's advisory committee meeting regarding the use of surgical mesh in pelvic organ prolapse.  AMS remains focused on physician and patient education activities as part of an overall effort to continue to encourage physicians and patients to discuss the risks and benefits of AMS's surgical mesh devices as an important treatment option for patients who suffer from stress urinary incontinence and pelvic organ prolapse.

HEALTHTRONICS

Services sales of $54 million for the third quarter 2012 represented an increase of 1 percent over the same period last year.  Third quarter growth for HealthTronics' was driven by the increasing sales of lab services and the strategic addition of electronic medical records to HealthTronics' offerings.  The company expects enhanced top-line growth from its Services segment in 2012 and beyond from the recent addition of HealthTronics' electronic medical records offering that is focused on practices specializing in urology and an expanding set of partnerships in HealthTronics' Endocare® cryoablation therapy business.

2012 Financial Guidance

Endo's estimates are based on actual results for the nine months ended September 30, 2012 and management's current belief about prescription trends, pricing levels, inventory levels and the anticipated timing of future product launches and events.  The company's guidance for reported (GAAP) earnings per share does not include any estimates for the potential future changes in the fair value of contingent consideration or for potential new corporate development transactions.  For the full year ended Dec 31, 2012, Endo estimates:

  • Total revenue of approximately $3.05 billion 
  • Total Endo Pharmaceuticals segment revenue of approximately $1.665 billion 
  • Total Qualitest segment revenue of approximately $660 million 
  • Total AMS segment revenue of approximately $510 million
  • Total HealthTronics segment revenue of approximately $220 million
  • Reported (GAAP) diluted earnings per share to be between $0.87 and $0.97
  • Adjusted diluted earnings per share to be between $5.00 and $5.10
  • Cash flow from operations of at least $600 million 
  • Capital expenditures to be approximately $120 million

The company's 2012 guidance is based on certain assumptions including:

  • Adjusted gross margin of between 68 percent and 69 percent
  • Adjusted effective tax rate of between 30.5 percent and 31.5 percent
  • Weighted average number of common shares outstanding of approximately 120 million shares for the year ended Dec 31, 2012

Balance Sheet Update

During the third quarter of 2012, Endo made mandatory payments of approximately $28 million and voluntary prepayments of approximately $73 million to reduce the outstanding principal of term loan debt associated with the acquisition of AMS.  This brings the total repayments on this debt to approximately $624 million, inclusive of $538 million in cumulative voluntary prepayments, through third quarter 2012. 

Additionally, during the third quarter of 2012, Endo repurchased approximately $100 million of its common stock following the Board of Directors' authorization to repurchase up to $450 million of its common stock through March 2015.  Additional repurchases may vary based on market conditions, securities law limitations and other factors.

Conference Call Information

Endo will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m. ET.  Investors and other interested parties may call 866-711-8198 (domestic) or +1 617-597-5327 (international) and enter passcode 82681027.  Please dial in 10 minutes prior to the scheduled start time.

A replay of the call will be available from Nov 5 at 10:30 a.m. ET until 12:00 p.m. ET on Nov. 19, 2012 by dialing 888-286-8010 (domestic) or +1 617-801-6888 (international) and entering passcode 66955070.

A simultaneous webcast of the call can be accessed by visiting www.endo.com.  In addition, a replay of the webcast will be available until 12:00 p.m. ET on Nov. 19, 2012.  The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.

Supplemental Financial Information

The following tables provide a reconciliation of our reported (GAAP) statements of operations to our adjusted statements of operations for each of the three months ended September 30, 2012 and 2011 (in thousands, except per share data):

 

 

Three Months Ended September 30, 2012 (unaudited)

 Actual Reported  (GAAP)

Adjustments

Adjusted

REVENUES

$

750,482

$

$

750,482

COSTS AND EXPENSES:

Cost of revenues

294,267

(52,762)

(1)

241,505

Selling, general and administrative

210,446

(10,480)

(2)

199,966

Research and development

48,952

(6,421)

(3)

42,531

Patent litigation settlement items, net

(46,238)

46,238

(4)

Litigation-related contingencies

82,600

(82,600)

(5)

Asset impairment charges

11,163

(11,163)

(6)

Acquisition-related and integration items, net

5,776

(5,776)

(7)

OPERATING INCOME

$

143,516

$

122,964

$

266,480

INTEREST EXPENSE, NET

45,505

(5,209)

(8)

40,296

NET LOSS ON EXTINGUISHMENT OF DEBT

1,789

(1,789)

(9)

OTHER EXPENSE (INCOME), NET

(250)

(250)

INCOME BEFORE INCOME TAX

$

96,472

$

129,962

$

226,434

INCOME TAX

28,287

30,678

(10)

58,965

CONSOLIDATED NET INCOME

$

68,185

$

99,284

$

167,469

Less: Net income attributable to noncontrolling interests

14,376

14,376

NET INCOME ATTRIBUTABLE TO ENDO HEALTH

SOLUTIONS INC.

$

53,809

$

99,284

$

153,093

DILUTED (LOSS) EARNINGS PER SHARE

$

0.45

$

1.28

DILUTED WEIGHTED AVERAGE SHARES

119,579

119,579

Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations:

(1)

To exclude amortization of commercial intangible assets related to marketed products of $55,999, net milestone payments of $1,440, an adjustment to the accrual for the payment to Impax related to sales of OPANA ER of $(6,000) and certain integration costs and separation benefits incurred in connection with continued efforts to enhance the company's operations of $1,323.

(2)

To exclude certain integration costs and separation benefits incurred in connection with continued efforts to enhance the company's operations of $7,744 and amortization of customer relationships of $2,736.

(3)

To exclude milestone payments to partners of $3,898 and certain integration costs and separation benefits incurred in connection with continued efforts to enhance the company's operations of $2,523.

(4)

To exclude the net impact of the Watson litigation settlement.

(5)

To exclude the net impact of accruals for litigation-related contingencies.

(6)

To exclude asset impairment charges.

(7)

To exclude acquisition-related and integration costs of $5,680 and a loss of $96 recorded to reflect the change in fair value of the contingent consideration associated with the Qualitest acquisition.

(8)

To exclude additional interest expense as a result of adopting ASC 470-20.

(9)

To exclude the unamortized debt issuance costs written off and recorded as a loss on extinguishment of debt upon our third quarter 2012 prepayments on our Term Loan indebtedness.

(10)

To reflect the cash tax savings results from our recent acquisitions and the tax effect of the pre-tax adjustments above at applicable tax rates. 

 

 

Three Months Ended September 30, 2011 (unaudited)

 Actual Reported  (GAAP)

Adjustments

Adjusted

REVENUES

$

759,078

$

$

759,078

COSTS AND EXPENSES:

Cost of revenues

302,172

(80,625)

(1)

221,547

Selling, general and administrative

244,359

(15,761)

(2)

228,598

Research and development

43,884

(2,355)

(3)

41,529

Asset impairment charges

22,691

(22,691)

(4)

Acquisition-related and integration items, net

5,818

(5,818)

(5)

OPERATING INCOME

$

140,154

$

127,250

$

267,404

INTEREST EXPENSE, NET

52,792

(4,754)

(6)

48,038

OTHER INCOME, NET

(3,000)

2,636

(7)

(364)

INCOME BEFORE INCOME TAX

$

90,362

$

129,368

$

219,730

INCOME TAX

34,057

18,928

(8)

52,985

CONSOLIDATED NET INCOME

$

56,305

$

110,440

$

166,745

Less: Net income attributable to noncontrolling interests

15,656

15,656

NET INCOME ATTRIBUTABLE TO ENDO HEALTH

SOLUTIONS INC.

$

40,649

$

110,440

$

151,089

DILUTED (LOSS) EARNINGS PER SHARE

$

0.34

$

1.25

DILUTED WEIGHTED AVERAGE SHARES

120,847

120,847

Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations:

(1)

To exclude amortization of commercial intangible assets related to marketed products of $55,337, the impact of inventory step-up recorded as part of acquisition accounting of $23,937 and certain integration costs and separation benefits incurred in connection with continued efforts to enhance the company's operations of $1,351.

(2)

To exclude certain integration costs and separation benefits incurred in connection with continued efforts to enhance the company's operations of $12,252 and amortization of customer relationships of $3,509.

(3)

To exclude milestone and upfront payments to partners.

(4)

To exclude asset impairment charges.

(5)

To exclude acquisition-related and integration costs of $6,046 and a gain of $(228) recorded to reflect the change in fair value of the contingent consideration associated with the Indevus and Qualitest acquisitions.

(6)

To exclude additional interest expense as a result of adopting ASC 470-20.

(7)

To exclude the gain on hedging activities for foreign currencies.

(8)

To reflect the cash tax savings results from our recent acquisitions and the tax effect of the pre-tax adjustments above at applicable tax rates. 

 

The following tables provide a reconciliation of our reported (GAAP) statements of operations to our adjusted statements of operations for each of the nine months ended September 30, 2012 and 2011 (in thousands, except per share data):

 

 

Nine Months Ended September 30, 2012 (unaudited)

 Actual Reported  (GAAP)

Adjustments

Adjusted

REVENUES

$

2,226,303

$

$

2,226,303

COSTS AND EXPENSES:

Cost of revenues

953,657

(272,857)

(1)

680,800

Selling, general and administrative

698,522

(30,044)

(2)

668,478

Research and development

183,067

(56,201)

(3)

126,866

Patent litigation settlement items, net

85,123

(85,123)

(4)

Litigation-related contingencies

82,600

(82,600)

(5)

Asset impairment charges

54,163

(54,163)

(6)

Acquisition-related and integration items, net

16,580

(16,580)

(7)

OPERATING INCOME

$

152,591

$

597,568

$

750,159

INTEREST EXPENSE, NET

138,386

(15,354)

(8)

123,032

NET LOSS ON EXTINGUISHMENT OF DEBT

7,215

(7,215)

(9)

OTHER EXPENSE, NET

498

(300)

(10)

198

(LOSS) INCOME BEFORE INCOME TAX

$

6,492

$

620,437

$

626,929

INCOME TAX

(9,263)

182,820

(11)

173,557

CONSOLIDATED NET (LOSS) INCOME

$

15,755

$

437,617

$

453,372

Less: Net income attributable to noncontrolling interests

39,826

39,826

NET (LOSS) INCOME ATTRIBUTABLE TO ENDO HEALTH SOLUTIONS INC.

$

(24,071)

$

437,617

$

413,546

DILUTED (LOSS) EARNINGS PER SHARE

$

(0.21)

$

3.42

DILUTED WEIGHTED AVERAGE SHARES

116,688

121,083

Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations:

(1)

To exclude amortization of commercial intangible assets related to marketed products of $162,414, the impact of inventory step-up recorded as part of acquisition accounting of $880, the accrual for the payment to Impax related to sales of OPANA ER of $104,000, net milestone payments of $2,927 and certain integration costs and separation benefits incurred in connection with continued efforts to enhance the company's operations of $2,636.

(2)

To exclude certain integration costs and separation benefits incurred in connection with continued efforts to enhance the company's operations of $21,799 and amortization of customer relationships of $8,245.

(3)

To exclude milestone payments to partners of $53,678 and certain integration costs and separation benefits incurred in connection with continued efforts to enhance the company's operations of $2,523.

(4)

To exclude the net impact of the Watson litigation settlement.

(5)

To exclude the net impact of accruals for litigation-related contingencies.

(6)

To exclude asset impairment charges.

(7)

To exclude acquisition-related and integration costs of $16,552 and a loss of $28 recorded to reflect the change in fair value of the contingent consideration associated with the Qualitest acquisition.

(8)

To exclude additional interest expense as a result of adopting ASC 470-20.

(9)

To exclude the unamortized debt issuance costs written off and recorded as a loss on extinguishment of debt upon our 2012 prepayments on our Term Loan indebtedness.

(10)

To exclude milestone payments to partners.

(11)

To reflect the cash tax savings results from our recent acquisitions and the tax effect of the pre-tax adjustments above at applicable tax rates.

 

 

Nine Months Ended September 30, 2011 (unaudited)

 Actual Reported  (GAAP)

Adjustments

Adjusted

REVENUES

$

1,926,715

$

$

1,926,715

COSTS AND EXPENSES:

Cost of revenues

770,427

(183,640)

(1)

586,787

Selling, general and administrative

581,878

(20,177)

(2)

561,701

Research and development

126,854

(18,346)

(3)

108,508

Asset impairment charges

22,691

(22,691)

(4)

Acquisition-related and integration items, net

29,517

(29,517)

(5)

OPERATING INCOME

$

395,348

$

274,371

$

669,719

INTEREST EXPENSE, NET

97,142

(14,014)

(6)

83,128

NET LOSS ON EXTINGUISHMENT OF DEBT

8,548

(8,548)

(7)

OTHER INCOME, NET

(2,777)

2,636

(8)

(141)

INCOME BEFORE INCOME TAX

$

292,435

$

294,297

$

586,732

INCOME TAX

100,283

45,349

(9)

145,632

CONSOLIDATED NET INCOME

$

192,152

$

248,948

$

441,100

Less: Net income attributable to noncontrolling interests

41,133

41,133

NET INCOME ATTRIBUTABLE TO ENDO HEALTH

SOLUTIONS INC.

$

151,019

$

248,948

$

399,967

DILUTED (LOSS) EARNINGS PER SHARE

$

1.24

$

3.29

DILUTED WEIGHTED AVERAGE SHARES

121,432

121,432

Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations:

(1)

To exclude amortization of commercial intangible assets related to marketed products of $132,571, the impact of inventory step-up recorded as part of acquisition accounting of $40,718, certain integration costs and separation benefits incurred in connection with continued efforts to enhance the company's operations of $1,351 and milestone payments to partners of $9,000.

(2)

To exclude certain integration costs and separation benefits incurred in connection with continued efforts to enhance the company's operations of $16,247 and amortization of customer relationships of $3,930.

(3)

To exclude milestone and upfront payments to partners.

(4)

To exclude asset impairment charges.

(5)

To exclude acquisition-related and integration costs of $36,975 and a gain of $(7,458) recorded to reflect the change in fair value of the contingent consideration associated with the Indevus and Qualitest acquisitions. 

(6)

To exclude additional interest expense as a result of adopting ASC 470-20.

(7)

To exclude the unamortized debt issuance costs written off and recorded as a loss on extinguishment of debt upon the early termination of our 2010 Credit Facility.

(8)

To exclude the gain on hedging activities for foreign currencies.

(9)

To reflect the cash tax savings results from our recent acquisitions and the tax effect of the pre-tax adjustments above at applicable tax rates.

 

See Endo's Current Report on Form 8-K filed today with the Securities and Exchange Commission for an explanation of Endo's reasons for using non-GAAP measures.

 

Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per Share Guidance for 2012

Year Ending

December 31, 2012

Projected GAAP diluted income per common share

$

0.87

To

$

0.97

Upfront and milestone-related payments to partners

0.52

0.52

Amortization of commercial intangible assets and inventory step-up

1.90

1.90

Acquisition and integration costs related to recent acquisitions.

0.42

0.42

One-time payment now expected to be made to Impax Labs

0.87

0.87

Litigation-related contingencies

0.69

0.69

Watson litigation settlement

0.71

0.71

Impairment of long-lived assets

0.45

0.45

Interest expense adjustment for ASC 470-20 and other treasury related items

0.23

0.23

Tax effect of pre-tax adjustments at the applicable tax rates and certain other

expected cash tax savings as a result of recent acquisitions

(1.66)

(1.66)

Diluted adjusted income per common share guidance

$

5.00

To

$

5.10

 

The company's guidance is being issued based on certain assumptions including:

  • Certain of the above amounts are based on estimates and there can be no assurance that Endo will achieve these results.
  • Includes all completed business development transactions as of Nov 5, 2012.

About Endo Endo Health Solutions Inc. (Endo) is a US-based diversified healthcare company that is redefining healthcare value by finding solutions for the unmet needs of patients along care pathways for pain management, pelvic health, urology, endocrinology and oncology. Through our operating companies: Endo Pharmaceuticals, Qualitest, AMS and HealthTronics, Endo is dedicated to improving care through a combination of branded products, generics, devices, technology and services that creates maximum value for patients, providers and payers alike. Learn more at www.endo.com.

(Tables Attached)

The following tables present Endo's unaudited Net Revenues for the three and nine months ended September 30, 2012 and 2011:

Endo Health Solutions Inc.

Net Revenues (unaudited)

(in thousands)

Three Months Ended September 30,

Percent Growth

Nine Months Ended September 30,

Percent Growth

2012

2011

2012

2011

Endo Pharmaceuticals:

LIDODERM®

$

238,282

$

207,364

15

%

$

676,302

$

592,929

14

%

OPANA® ER

62,232

97,753

(36

%

236,731

275,221

(14)

%

Voltaren® Gel

35,483

36,260

(2)

%

79,173

104,213

(24)

%

PERCOCET®

24,209

28,130

(14)

%

73,413

82,765

(11)

%

FROVA®

15,706

14,815

6

%

45,352

42,186

8

%

SUPPRELIN® LA

14,534

12,695

14

%

42,777

36,432

17

%

VANTAS®

4,114

5,013

(18)

%

12,352

10,612

16

%

VALSTAR®

8,394

6,295

33

%

20,717

16,220

28

%

FORTESTA® Gel

8,823

8,409

5

%

21,526

9,468

127

%

Other Branded Products

933

4,948

(81)

%

1,788

17,527

(90)

%

Royalty and Other Revenue

3,935

3,829

3

%

12,874

11,719

10

%

Total Endo Pharmaceuticals

$

416,645

$

425,511

(2)

%

$

1,223,005

$

1,199,292

2

%

Total Qualitest

$

166,070

$

147,975

12

%

$

471,310

$

415,431

13

%

American Medical Systems:

Men's Health

58,316

66,548

(12)

%

192,728

76,316

153

%

Women's Health

29,399

38,240

(23)

%

95,763

46,027

108

%

BPH Therapy

25,589

26,731

(4)

%

83,110

35,988

131

%

Total AMS

113,304

131,519

(14)

%

371,601

158,331

135

%

HealthTronics

54,463

54,073

1

%

160,387

153,661

4

%

Total Revenue

750,482

759,078

(1)

%

2,226,303

1,926,715

16

%

 

The following table presents Endo's unaudited Pro forma Net Revenues for the seven quarters ended September 30, 2012 giving effect to the AMS acquisition as if it had occurred on January 1, 2011:

 

Endo Health Solutions Inc. Net Pro Forma Revenues (unaudited) (in thousands)

2011

2012

Endo Pharmaceuticals:

Q1

Q2

Q3

Q4

Q1

Q2

Q3

LIDODERM®

$

189,725

$

195,840

$

207,364

$

232,252

$

210,014

$

228,006

$

238,282

OPANA® ER

84,615

92,853

97,753

109,118

81,086

93,413

62,232

Voltaren® Gel

31,298

36,655

36,260

38,488

43,690

35,483

PERCOCET®

26,960

27,675

28,130

21,835

23,380

25,824

24,209

FROVA®

13,208

14,163

14,815

15,994

15,644

14,002

15,706

SUPPRELIN® LA

11,222

12,515

12,695

13,683

13,446

14,797

14,534

VANTAS®

3,545

2,054

5,013

8,366

3,892

4,346

4,114

VALSTAR®

4,801

5,124

6,295

5,301

6,236

6,087

8,394

FORTESTA® Gel

(969)

2,028

8,409

5,401

5,822

6,881

8,823

Other Branded Products

6,970

5,609

4,948

4,224

(265)

1,120

933

Royalty and Other Revenue

4,221

3,751

3,829

3,813

4,319

4,620

3,935

Total Endo Pharmaceuticals

$

375,596

$

398,267

$

425,511

$

458,475

$

363,574

$

442,786

$

416,645

Total Qualitest

$

134,409

$

133,047

$

147,975

$

151,423

$

145,345

$

159,895

$

166,070

American Medical Systems:

Men's Health

67,407

47,790

66,548

69,520

67,440

66,972

58,316

Women's Health

45,325

46,689

38,240

39,482

33,898

32,466

29,399

BPH Therapy

28,054

29,784

26,731

32,966

28,828

28,693

25,589

Total AMS

$

140,786

$

124,263

$

131,519

$

141,968

$

130,166

$

128,131

$

113,304

HealthTronics(1)

50,103

49,485

54,073

51,540

51,548

54,376

54,463

Total Revenue

$

700,894

$

705,062

$

759,078

$

803,406

$

690,633

$

785,188

$

750,482

(1)  The HealthTronics segment does not include the pro forma impact of pre-acquisition revenues from the recently acquired electronic medical records providers, Intuitive Medical Software (IMS) and meridianEMR, Inc.

 

The following table presents unaudited condensed consolidated Balance Sheet data at September 30, 2012 and December 31, 2011:

 

September 30, 2012

December 31, 2011

ASSETS

CURRENT ASSETS:

Cash and cash equivalents

$

256,917

$

547,620

Accounts receivable, net

759,594

733,222

Inventories, net

363,747

262,419

Other assets

332,241

244,835

Total current assets

$

1,712,499

$

1,788,096

PROPERTY, PLANT AND EQUIPMENT, NET

333,119

297,731

GOODWILL

2,569,288

2,558,041

OTHER INTANGIBLES, NET

2,285,187

2,504,124

OTHER ASSETS

120,698

144,591

TOTAL ASSETS

$

7,020,791

$

7,292,583

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts payable and accrued expenses

$

1,224,658

$

993,216

Other current liabilities

130,974

128,562

Total current liabilities

$

1,355,632

$

1,121,778

DEFERRED INCOME TAXES

581,975

617,677

LONG-TERM DEBT, LESS CURRENT PORTION, NET

3,069,518

3,424,329

OTHER LIABILITIES

83,149

89,208

STOCKHOLDERS' EQUITY:

Total Endo Health Solutions Inc. stockholders' equity

$

1,868,200

$

1,977,690

Noncontrolling interests

62,317

61,901

Total stockholders' equity

$

1,930,517

$

2,039,591

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$

7,020,791

$

7,292,583

 

The following table presents unaudited condensed consolidated Statement of Cash Flow data for the nine months ended September 30, 2012 and 2011:

Nine Months Ended September 30,

2012

2011

OPERATING ACTIVITIES:

Consolidated net income

$

15,755

$

192,152

Adjustments to reconcile consolidated net income to Net cash provided by

operating activities

Depreciation and amortization

211,780

169,187

Stock-based compensation

44,532

34,224

Amortization of debt issuance costs and premium / discount

27,101

24,283

Other

(25,771)

10,433

Changes in assets and liabilities which provided (used) cash:

23,735

(11,748)

Net cash provided by operating activities

297,132

418,531

INVESTING ACTIVITIES:

Purchases of property, plant and equipment, net

(89,047)

(38,462)

Acquisitions, net of cash acquired

(3,210)

(2,368,357)

Other

13,100)

39,631

Net cash used in investing activities

(79,157)

(2,367,188)

FINANCING ACTIVITIES:

Purchase of common stock, net of issuance of common stock from treasury

(151,394)

(34,702)

Cash distributions to noncontrolling interests

(39,234)

(39,392)

Principal (payments) on indebtedness, net of proceeds

(334,701)

2,030,449

Exercise of Endo Health Solutions Inc. stock options

15,317

21,780

Other

1,239

(76,418)

Net cash (used in) provided by financing activities

(508,773)

1,901,717

Effect of foreign exchange rate

95

397

NET DECREASE IN CASH AND CASH EQUIVALENTS

(290,703)

(46,543)

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD

547,620

466,214

CASH AND CASH EQUIVALENTS, END OF PERIOD

$

256,917

$

419,671

 

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements.  Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE Endo Health Solutions



RELATED LINKS

http://www.endo.com